Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments
This year has seen pivotal advancements in medical innovation. The US Food and Drug Administration (
US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains
Over the last few decades, the United States and Europe have saved trillions of dollars by importing
BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans
Over
the last two years, there has been a significant surge in layoffs by
pharmaceutical and biote
Novartis, GSK, Sanofi, BMS shell out over US$ 10 bn in dealmaking, as mid-size deals take centerstage in 2024
The world of pharmaceuticals and biotechnology continued to evolve
this year with strategic allianc
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea
Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of
Big Pharma bets big on AI’s US$ 148 bn potential to revolutionize healthcare industry
Artificial intelligence (AI) is changing the world and bringing
efficiencies across all industries.
Top Pharma Companies & Drugs in 2023: Merck’s Keytruda emerges as top-selling drug; Novo, Lilly sales skyrocket
The pharma industry clearly recalibrated itself in 2023, turning its focus away from Covid and onto